CAM Group Holding A S held its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the second quarter, Holdings Channel reports. The institutional investor owned 107,575 shares of the company’s stock at the end of the second quarter. CAM Group Holding A S’s holdings in BioMarin Pharmaceutical were worth $8,369,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also modified their holdings of the company. Adage Capital Partners GP L.L.C. raised its position in shares of BioMarin Pharmaceutical by 316.3% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,052,900 shares of the company’s stock valued at $86,843,000 after buying an additional 800,000 shares during the period. Candriam Luxembourg S.C.A. raised its position in shares of BioMarin Pharmaceutical by 18.5% in the second quarter. Candriam Luxembourg S.C.A. now owns 247,100 shares of the company’s stock valued at $19,225,000 after buying an additional 38,628 shares during the period. ING Groep NV purchased a new position in shares of BioMarin Pharmaceutical during the second quarter valued at $57,357,000. Strs Ohio raised its position in shares of BioMarin Pharmaceutical by 50.7% in the second quarter. Strs Ohio now owns 491,556 shares of the company’s stock valued at $38,243,000 after buying an additional 165,472 shares during the period. Finally, State Street Corp raised its position in shares of BioMarin Pharmaceutical by 5.6% in the first quarter. State Street Corp now owns 3,286,743 shares of the company’s stock valued at $271,074,000 after buying an additional 175,733 shares during the period. 93.08% of the stock is currently owned by institutional investors.
Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) traded down 0.06% during trading on Tuesday, reaching $85.40. 1,036,394 shares of the company’s stock were exchanged. The company’s market capitalization is $13.96 billion. BioMarin Pharmaceutical Inc. has a 52-week low of $62.12 and a 52-week high of $118.48. The company has a 50 day moving average price of $94.32 and a 200-day moving average price of $89.71.
BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Thursday, August 4th. The company reported ($2.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by $2.09. BioMarin Pharmaceutical had a negative net margin of 54.53% and a negative return on equity of 11.99%. The business earned $300.10 million during the quarter, compared to analyst estimates of $278.75 million. During the same period in the previous year, the firm posted ($0.51) EPS. The firm’s revenue for the quarter was up 20.0% on a year-over-year basis. On average, equities analysts forecast that BioMarin Pharmaceutical Inc. will post ($3.95) earnings per share for the current year.
Several research analysts recently weighed in on BMRN shares. JPMorgan Chase & Co. increased their target price on BioMarin Pharmaceutical from $120.00 to $127.00 and gave the stock an “overweight” rating in a research report on Friday, August 5th. Zacks Investment Research downgraded BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Thursday, July 14th. Piper Jaffray Cos. reiterated an “overweight” rating on shares of BioMarin Pharmaceutical in a report on Friday, August 19th. Leerink Swann reiterated an “outperform” rating and issued a $107.00 price target on shares of BioMarin Pharmaceutical in a report on Wednesday, June 22nd. Finally, Goldman Sachs Group Inc. upgraded BioMarin Pharmaceutical to a “neutral” rating in a report on Friday, October 7th. Three analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. BioMarin Pharmaceutical currently has an average rating of “Buy” and an average target price of $118.31.
In other BioMarin Pharmaceutical news, VP Brian Mueller sold 287 shares of the business’s stock in a transaction on Monday, August 1st. The shares were sold at an average price of $100.00, for a total transaction of $28,700.00. Following the completion of the transaction, the vice president now owns 14,260 shares of the company’s stock, valued at approximately $1,426,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jean Jacques Bienaime sold 137,368 shares of the business’s stock in a transaction on Friday, September 16th. The stock was sold at an average price of $95.34, for a total transaction of $13,096,665.12. Following the transaction, the chief executive officer now directly owns 421,161 shares of the company’s stock, valued at approximately $40,153,489.74. The disclosure for this sale can be found here. 2.50% of the stock is currently owned by corporate insiders.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).
Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).
Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.